Cambium Bio Limited has released a press release.
CEO Presentation to 2019 Annual General Meeting
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Cambium Bio
- Chairmans Address to Shareholders
- Japanese Biotech Fund takes up all Rights Issue Shortfall
- Regeneus receives A$1.5 million in R&D Tax Incentives
- Appendix 4E
- Restructuring results in 50% reduction in operating costs
Later from Cambium Bio
- AGC Agreement termination paves way for commercial partner
- Directors provide $4m loan facility
- Half-Year Results & Business Update
- Regeneus signs MOU with Kyocera Corporation
- Regeneus receives A$1.6M milestone payment from Kyocera
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio